---
title: "Top 10 HK Stock Gainers (12.11)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269349473.md"
description: "MOBVISTA(01860) rose 14.76%, with a trading turnover 647.9 Million HKD, and a year-to-date rose 96.8%. XUANZHUBIO-B(02575) rose 14.16%, with a trading turnover 47.2 Million HKD, and a year-to-date rose 567.2%. BAO PHARMA-B(02659) rose 9.52%, with a trading turnover 144.5 Million HKD, and a year-to-date rose 161.6%."
datetime: "2025-12-11T08:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269349473.md)
  - [en](https://longbridge.com/en/news/269349473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269349473.md)
---

# Top 10 HK Stock Gainers (12.11)

Hang Seng Index has fell 0.04%, with a year-to-date rose 27.3%; Hang Seng TECH Index has fell 0.83%, with a year-to-date rose 23.9%.

MOBVISTA(01860) rose 14.76%, with a trading turnover 647.9 Million HKD, and a year-to-date rose 96.8%.

XUANZHUBIO-B(02575) rose 14.16%, with a trading turnover 47.2 Million HKD, and a year-to-date rose 567.2%.

BAO PHARMA-B(02659) rose 9.52%, with a trading turnover 144.5 Million HKD, and a year-to-date rose 161.6%.

### Related Stocks

- [01860.HK](https://longbridge.com/en/quote/01860.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)
- [02659.HK](https://longbridge.com/en/quote/02659.HK.md)
- [08030.HK](https://longbridge.com/en/quote/08030.HK.md)
- [00259.HK](https://longbridge.com/en/quote/00259.HK.md)
- [06969.HK](https://longbridge.com/en/quote/06969.HK.md)
- [00667.HK](https://longbridge.com/en/quote/00667.HK.md)
- [02208.HK](https://longbridge.com/en/quote/02208.HK.md)
- [00800.HK](https://longbridge.com/en/quote/00800.HK.md)
- [01072.HK](https://longbridge.com/en/quote/01072.HK.md)

## Related News & Research

- [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md)
- [Mobvista Overhauls RSU Scheme to Expand Incentives and Tighten Governance](https://longbridge.com/en/news/278856670.md)
- [Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology](https://longbridge.com/en/news/280309450.md)
- [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md)
- [Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib](https://longbridge.com/en/news/283291980.md)